Nachrichten zur Eli Lilly & Co. Aktie

Aktis Oncology upsizes IPO by 50%, attracts $100 million from Eli Lilly By Investing.com

Aktis Oncology upsizes IPO by 50%, attracts $100 million from Eli Lilly…

Warning: This Skyrocketing Stock Has a Hidden Risk

Novo Nordisks new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the…

Eli Lillys 2026 Resolution: Volume Is The New Price

…

Ventyx Biosciences stock surges after Eli Lilly acquisition talks By Investing.com

Ventyx Biosciences stock surges after Eli Lilly acquisition talks…

Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports

Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on…

Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?

Eli Lilly offers investors safety and growth.…

Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its…

3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)

Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.…

Is It Time to Dump Your Shares of Eli Lilly?

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.…

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

Novo Nordisk and Eli Lilly are expected to bring GLP-1 pills to market in the new year, which is expected…

Market Holds Near Highs, Key Support With 2025 Ending

Eli Lilly, Shopify lead seven stocks near buy points.…

Can Amgens MariTide Take on Leaders in the Obesity Space?

AMGNs MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push…

Biogen: Competing With Eli Lillys Kisunla, Safety Gives Market Edge

…

Novo Nordisk, Eli Lilly cut obesity drug prices in China By Investing.com

Novo Nordisk, Eli Lilly cut obesity drug prices in China…

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%.…

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own…

Top Analyst Reports for Eli Lilly, Shell & ICICI Bank

LLYs strong GLP-1 demand, international launches and new drug contributions highlight why it leads todays top analyst reports lineup.…

These are the worlds most important stocks heading into 2026, according to Bank of America

Bank of America found names such as Microsoft and Eli Lilly to be among the most pivotal stocks in global…

Eli Lilly’s pill solves the biggest problem with weight loss

Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem…

Der Durchbruch nach der GLP-1-Diät! Wie eine Pille von Eli Lilly den Jo-Jo-Effekt stoppen soll!

Die Abnehmrevolution geht in die nächste Runde. Während Injektionspräparate den GLP-1-Boom ausgelöst haben, rückt nun eine einfache Tablette in den…

Better Buy in 2026: UnitedHealth Group or Eli Lilly?

These industry titans have gone in opposite directions this year; is that likely to change?…

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close.…

Better Buy in 2026: Pfizer or Eli Lilly?

These two stocks have been going in opposite directions over the past few years.…

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron,…

Eli Lilly Scores Another Major Win: Time to Buy?

The company is running circles around its competition.…

Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk

These two healthcare stocks have strong growth prospects, but theyve been going in opposite directions.…

Eli Lilly or Merck: Where Should Investors Put Their Money?

LLYs explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer…

Where Will Eli Lilly Be in 10 Years?

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.…

US-Justiz bündelt „Erblindungs“-Klagen gegen Novo Nordisk und Eli Lilly

In den USA entsteht neben der ohnehin schon riesigen GLP-1-Prozesswelle ein zweites Sammelverfahren  – diesmal mit dem schwerwiegenden Vorwurf, Abnehm- und…

2 Predictions for Eli Lilly in 2026

Can anything stop this high-flying drugmaker?…

Eli Lilly Just Delivered Fantastic News to Investors

Eli Lilly shares have climbed in the double digits this year.…

Eli Lilly: The Right Long-Term Strategy

…

Eli Lilly Further Cements Itself As The King Of Weight Loss

…

Why the Market Dipped But Eli Lilly (LLY) Gained Today

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its…

Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive By Investing.com

Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive…

Eli Lillys Next-Generation Obesity Drug Secures First Phase III Win

LLYs retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.…

Eli Lilly: Retatrutid liefert neue klinische Bestmarken und treibt Umsatz und Gewinn!

Der US-Pharmakonzern Eli Lilly verschärft den Wettbewerb im Markt für Adipositas- und Stoffwechseltherapien. Neue Studiendaten zu dem experimentellen Wirkstoff Retatrutid…

Dow Hit New High; Broadcom Sees AI Chip Sales Doubling

Eli Lilly, Urban Outfitters and more flashed buy signals while the Nasdaq slashed early losses.…

Eli Lillys next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection…

Studienerfolg: Neues Lilly-Medikament senkt Gewicht - Knieschmerz verringert

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hat mit einer Weiterentwicklung seiner Gewichtssenker in klinischen Tests…

Oracle, Adobe and Broadcom fall premarket; Eli Lilly gains By Investing.com

Oracle, Adobe and Broadcom fall premarket; Eli Lilly gains…

Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide

Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment…

Abivax stock pops on Eli Lilly takeover speculation

Abivax SA (NASDAQ:ABVX, EPA:ABVX), a French biotechnology firm, saw its US-listed shares jump more than 11% on rumors it may be…

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

That added production capacity for Eli Lillys obesity pill, orforglipron, is crucial as the company races to file for its…

Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Eli Lillys Mounjaro added to Chinas state insurance list for diabetes treatment

Eli Lillys popular drug Mounjaro will be added to Chinas state-run health insurance scheme from January 1 for patients with…

Eli Lilly, Pfizer Land on China’s First Private Insurance List

Eli Lilly & Co., Pfizer Inc. and Johnson & Johnson secured spots on China’s first innovative drug catalog, opening a…

Eli Lillys Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?

This is no reason to panic.…

Meet the Supercharged Growth Stock That Could Join Apple, Nvidia, Microsoft, and Alphabet in the $2 Trillion Club by 2028

Eli Lillys stock price and market cap are poised to explode with the GLP-1 market.…